Evidence map›Paper›PMID 27526792›Full record

ReviewCurrent pharmaceutical design2017

Cannabis Epidemiology: A Selective Review.

James C Anthony, Catalina Lopez-Quintero, Omayma Alshaarawy

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022
    Article
  19. Article
  20. Tobacco cigarette and cannabis use among new mothers.Addiction (Abingdon, England) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James C AnthonyCollege of Human Medicine, Michigan State University, West Fee Hall, 909 Fee Road, East Lansing, MI 48824-1030,. United States.
Catalina Lopez-Quintero
Omayma Alshaarawy

Funding

Training Program in Drug Dependence EpidemiologyT32DA021129 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2006 to 2016
$2.7M
Drug Dependence Epidemiology and EnviromicsK05DA015799 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2015
$1.4M
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on diseaseR00AT009156 · NCCIH · MICHIGAN STATE UNIVERSITY · PI ALSHAARAWY, OMAYMA O · 2018 to 2020
$744k
Using pre-clinical biomarkers and epidemiological models to assess the effects of cannabinoids on diseaseK99AT009156 · NCCIH · MICHIGAN STATE UNIVERSITY · PI ALSHAARAWY, OMAYMA O · 2016 to 2017
$181k
NCCIH NIH HHS K99 AT009156NCCIH NIH HHS R00 AT009156NIDA NIH HHS K05 DA015799NIDA NIH HHS T32 DA021129
6 · The paper itself

Abstract

backgroundGlobally, the most widely used set of compounds among the internationally regulated drugs is cannabis.

objectiveTo review evidence from epidemiological research on cannabis, organized in relation to this field's five main rubrics: quantity, location, causes, mechanisms, and prevention/ control.

methodThe review covers a selection of evidence from standardized population surveys, official statistics, and governmental reports, as well as published articles and books identified via MEDLINE, Web of Science, and Google Scholar as of July 2016.

resultsIn relation to quantity, an estimated 3% to 5% of the world population is thought to have tried a cannabis product, with at least one fairly recent use, mainly extra-medical and outside boundaries of prescribed use. Among cannabis users in the United States, roughly one in 7-8 has engaged in medical marijuana use. In relation to location, prevalence proportions reveal important variations across countries and between subgroups within countries. Regarding causes and mechanisms of starting to use cannabis, there is no compelling integrative and replicable conceptual model or theoretical formulation. Most studies of mechanisms have focused upon a 'gateway sequence' and person-to-person diffusion, with some recent work on disability-adjusted life years. A brief review of cannabis use consequences, as well as prevention and control strategies is also provided.

conclusionAt present, we know much about the frequency and occurrence of cannabis use, with too little replicable definitive evidence with respect to the other main rubrics. Given a changing regulatory environment for cannabis products, new institutions such as an independent International Cannabis Products Safety Commission may be required to produce evidence required to weigh benefits versus costs. It is not clear that governmentsponsored research will be sufficient to meet consumer demand for balanced points of view and truly definitive evidence.

Indexed as

CannabisMedical MarijuanaHumansMarijuana AbuseMedical MarijuanaCannabisepidemiologyincidencemarijuanamedical marijuanaprevalence

Identifiers

PMID27526792
PMCPMC5296933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.